Intellia Therapeutics (NTLA) CFO files Form 4 for sell-to-cover

Rhea-AI Filing Summary

Intellia Therapeutics EVP and CFO Edward J. Dulac III reported an automatic sale of company stock. On January 5, 2026, he sold 6,379 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations tied to restricted stock units that vested on January 1, 2026, and it is described as not being a voluntary trade by the executive. After this transaction, he beneficially owns 99,683 shares of Intellia Therapeutics common stock directly.

Insider Trade Summary

Net Seller: 6,379 shares ($58,751)

Net Sell 1 txn

Insider Dulac Edward J III

Role EVP, Chief Financial Officer

Sold 6,379 shs ($59K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,379	$9.21	$59K

Holdings After Transaction: Common Stock — 99,683 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/07/2026 - 04:02 PM Learn about SEC filing dates

FAQ

What insider transaction did Intellia Therapeutics (NTLA) report in this Form 4?

The filing reports that EVP and Chief Financial Officer Edward J. Dulac III sold 6,379 shares of Intellia Therapeutics common stock on January 5, 2026 at $9.21 per share.

Why did Intellia Therapeutics CFO Edward Dulac sell 6,379 NTLA shares?

The filing states the sale represents a mandatory “sell-to-cover” transaction to satisfy the reporting person’s tax withholding obligation upon the vesting of RSUs on January 1, 2026, and it is described as not a volitional trade.

How many Intellia Therapeutics shares does the CFO own after this transaction?

After the reported transaction, Edward J. Dulac III beneficially owns 99,683 shares of Intellia Therapeutics common stock, held directly.

What was the price per share for the Intellia Therapeutics insider sale?

The 6,379 shares of Intellia Therapeutics common stock reported in the sale were transacted at a price of $9.21 per share.

Is the Intellia Therapeutics CFO’s stock sale part of a trading plan?

The filing includes a general reference to Rule 10b5-1 instructions, but the reported transaction is specifically described as a mandatory sell-to-cover for tax withholding related to RSU vesting, rather than a discretionary trade.

What role does the reporting person hold at Intellia Therapeutics (NTLA)?

The reporting person, Edward J. Dulac III, is identified as an officer of Intellia Therapeutics, serving as EVP, Chief Financial Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dulac Edward J III

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		6,379	D	$9.21	99,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

	James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.